Skip to main content
Premium Trial:

Request an Annual Quote

Personalis: Kenneth Widder, Alan Colowick

Personalis has appointed Kenneth Widder to its board of directors. Widder currently serves on the boards of QuidelOrtho and Evoke Pharma. He has over 40 years of experience working with biomedical companies, including Sydnexis, OrphoMed, Sytera, NovaCardia, Santarus, and Molecular Biosystems. He was also a general partner at LVP Life Science Ventures and Windamere Venture Partners. He holds an MD from Northwestern University and was trained in pathology at Duke University.

The company also announced that Alan Colowick has resigned his position as a director of the company, effective June 12.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.